Betta Pharmaceuticals Co Ltd (SHE:300558) — Market Cap & Net Worth
Market Cap & Net Worth: Betta Pharmaceuticals Co Ltd (300558)
Betta Pharmaceuticals Co Ltd (SHE:300558) has a market capitalization of $2.84 Billion (CN¥19.44 Billion) as of September 16, 2026. Listed on the SHE stock exchange, this China-based company holds position #5077 globally and #871 in its home market, demonstrating a -4.33% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Betta Pharmaceuticals Co Ltd's stock price CN¥46.21 by its total outstanding shares 420733843 (420.73 Million). Also see 300558 current and non-current assets for a full breakdown of the balance sheet.
Betta Pharmaceuticals Co Ltd Market Cap History: 2016 to 2026
Betta Pharmaceuticals Co Ltd's market capitalization history from 2016 to 2026. Data shows growth from $4.43 Billion to $2.84 Billion (6.57% CAGR). Also see cash efficiency ratio of Betta Pharmaceuticals Co Ltd for how efficiently the company converts equity into cash flow.
Index Memberships
Betta Pharmaceuticals Co Ltd is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ChiNext
CNT
|
$1.14 Trillion | 0.25% | #69 of 100 |
Weight: Betta Pharmaceuticals Co Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Betta Pharmaceuticals Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Betta Pharmaceuticals Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Betta Pharmaceuticals Co Ltd stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.80x
Betta Pharmaceuticals Co Ltd's market cap is 0.80 times its annual revenue
Latest Price to Earnings (P/E) Ratio
9.41x
Betta Pharmaceuticals Co Ltd's market cap is 9.41 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $4.43 Billion | $1.04 Billion | $368.80 Million | 4.28x | 12.02x |
| 2017 | $3.81 Billion | $1.03 Billion | $257.73 Million | 3.72x | 14.80x |
| 2018 | $1.93 Billion | $1.22 Billion | $166.82 Million | 1.58x | 11.58x |
| 2019 | $3.98 Billion | $1.55 Billion | $230.82 Million | 2.56x | 17.24x |
| 2020 | $6.51 Billion | $1.87 Billion | $606.36 Million | 3.48x | 10.74x |
| 2021 | $4.86 Billion | $2.25 Billion | $383.07 Million | 2.16x | 12.68x |
| 2022 | $3.02 Billion | $2.38 Billion | $145.42 Million | 1.27x | 20.74x |
| 2023 | $3.16 Billion | $2.46 Billion | $348.03 Million | 1.29x | 9.08x |
| 2024 | $3.32 Billion | $2.89 Billion | $402.57 Million | 1.15x | 8.25x |
| 2025 | $2.87 Billion | $3.61 Billion | $305.33 Million | 0.80x | 9.41x |
Competitor Companies of 300558 by Market Capitalization
Companies near Betta Pharmaceuticals Co Ltd in the global market cap rankings as of September 16, 2026. Review 300558 intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Betta Pharmaceuticals Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
Betta Pharmaceuticals Co Ltd Historical Marketcap From 2016 to 2026
Between 2016 and today, Betta Pharmaceuticals Co Ltd's market cap moved from $4.43 Billion to $ 2.84 Billion, with a yearly change of 6.57%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥2.84 Billion | -1.03% |
| 2025 | CN¥2.87 Billion | -13.42% |
| 2024 | CN¥3.32 Billion | +5.09% |
| 2023 | CN¥3.16 Billion | +4.78% |
| 2022 | CN¥3.02 Billion | -37.93% |
| 2021 | CN¥4.86 Billion | -25.42% |
| 2020 | CN¥6.51 Billion | +63.72% |
| 2019 | CN¥3.98 Billion | +106.05% |
| 2018 | CN¥1.93 Billion | -49.37% |
| 2017 | CN¥3.81 Billion | -13.95% |
| 2016 | CN¥4.43 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Betta Pharmaceuticals Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.84 Billion USD |
| MoneyControl | $2.84 Billion USD |
| MarketWatch | $2.84 Billion USD |
| marketcap.company | $2.84 Billion USD |
| Reuters | $2.84 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Betta Pharmaceuticals Co Ltd
Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China and internationally. The company offers Icotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat first-line treatment of locally advanced or non-small-cell lung cancer (NSCLC); Ensartinib hydrochloride, an anaplastic lymphoma… Read more